Alcobra (ADHD) To Present At The American Society Of Clinical Psychopharmacology Annual Meeting And The Biotechnology Industry Organization (BIO) International Convention
6/9/2014 9:04:29 AM
TEL AVIV, Israel, June 9, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will be a featured speaker and presenter at the 2014 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) 2014 Annual Meeting, being held June 16-19, 2014 at the Westin Diplomat Hotel in Hollywood, Florida.
Help employers find you! Check out all the jobs and post your resume.
comments powered by